Annovis Bio Inc. (ANVS) stock has reached a new 52-week low, touching down at $4.05, with the $56 million market cap biotech ...

In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -33.06% over the last five trades and -35.

Annovis Bio (ANVS) is down -25.6%, or -$1.25 to $3.62.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...

Annovis Bio (ANVS) announced the pricing of an underwritten public offering of 5.25M shares of common stock and warrants to purchase 5,250,000 ...

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...

Annovis Bio (NYSE:ANVS) shares fell around 19% premarket on Monday after the company priced a securities offering to raise $21M. The sale comprises 5.25M shares of common stock and warrants to ...

MALVERN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage pharmaceutical company with a market capitalization of $67 million specializing in the development of treatments for neurodegenerative ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for ...

Late-stage clinical drug platform company Annovis Bio, Inc. (ANVS), Monday announced the pricing of 5.25 million common stock and ...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...